With a pharmaceutical market valued at $86.9 billion in 2022, it is understandable that legal issues specific to the pharmaceutical industry are becoming more prevalent. Whether the issue concerns traditional pharmaceutical drugs or medical devices, the Devlin Law Firm has the expertise to address your concerns.
Devlin Law Firm has devised a program for small and mid-sized pharmaceuticals companies to enter the U.S. market. The program is also scalable for larger companies who have already made the jump to the U.S. Our business model allows us to serve a wide range of client needs, from lone inventors to multi-million-dollar companies. We offer big firm experience and capabilities at a small, flexible, entrepreneurial-firm cost.
The Devlin Law Firm is happy to enter into a traditional hourly fee for service engagement with a competitive fee structure. However, given the Firm’s experience monetizing its clients’ intellectual property, the Firm is ideally suited to offer a non-traditional, hybrid fee structure. A monthly fee structure, which is based on an agreed monthly payment through the end of litigation gives the client piece of mind about a predictable monthly cost of litigation. The Firm can also offset the cost of the monthly fee utilizing a hybrid fee structure by pairing the fixed fee or monthly amounts with a contingent component paid out over time once the Firm is successful. In this way, the Firm has a vested interest in the success of the case, rather than just collecting its fees regardless of the end result.
The Firm also has extensive expertise in assisting with bringing generic drugs to market under an Abbreviated New Drug (ANDA) application. The Devlin Law Firm has assembled a team of ANDA litigators with expertise in representing both innovators and generic companies. Our strategic vision, coupled with our depth and breadth of experience, affords our clients unparalleled advantages in the quest for legal and business success.
For companies outside the United States attempting to bring a drug to market, the cost of entry can be difficult to overcome. For example, coming to market in the U.S. with a new generic product almost always involves patent litigation. With total fees and costs averaging over $4 million for a typical case, litigation is a significant barrier for most small to mid-sized pharmaceutical companies. As a result many pharmaceutical companies and API vendors forego lucrative opportunities available in the U.S.
Determining the best generic to bring to the U.S. market is a careful mix of what pharmaceutical will be most profitable and what will be easiest and most cost effective for the client to manufacture. While the attorneys are not pharmacologists, they can work with the client to select the best product and then assist the client through the ANDA application process.
Devlin Law Firm provides expert-level patent and intellectual property litigation, strategy, and management services to companies and individuals around the globe.
